- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35.
- Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398405.
- Van den Bosch F, Krulthof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy : effect of TNF-a blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
- Sheldon DG, Sawchuk LL, Kozarek RA Thielby RC. Twenty cases of peristomal pyoderma gangrenosum. Arch Surg 2000; 135:564-8.
- Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284:1546-8.
- Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 2001;137:930-3.
- Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharm Ther 2001;15:1639-46.
- MacDonald TT, Hutching s P, Choy MY, Murch S, Cooke A. Tumour-necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
- Murch SH, Braegger SP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
- Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-á blockade in rheumatoid arthritis. Clin Exp Immunol 1995;101:207-12.
- Cope AP, Londei M, Chu Nr, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/ CD3 complex : reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
- Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TCl (cytotoxic lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-9.
- D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopie and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-34.
Pyoderma Gangrenosum Associated with Crohn Disease: Effect of TNF- α Blockade with Infliximab
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.